Obesity Crisis: GLP-1 Drugs Bridge Evolution and Modernity

The Times of India article, featuring an interview with Professor Susan A. Jebb, Chair of the UK's Food Standards Agency, accurately highlights a critical global health crisis: humans are demonstrably fatter than ever before. This central claim is extensively verified by real-time information. The World Health Organization (WHO) reports that worldwide adult obesity rates more than doubled from 7% to 16% between 1990 and 2022, while childhood and adolescent obesity quadrupled from 2% to 8% in the same period. More than one billion people globally are now classified as obese. The article attributes this phenomenon to a fundamental mismatch between human evolution and modern living conditions. Our ancestors evolved in environments where food was scarce and physical activity was essential for survival, leading to genetic predispositions that encouraged efficient fat storage and eating freely when food was available. However, contemporary society offers abundant, palatable, and often cheaper, energy-dense food, coupled with increasingly sedentary lifestyles due to technological advancements and modern work. This creates an 'abnormal environment' where our evolutionary biology, which once provided a survival advantage (e.g., providing energy for a large brain), now contributes to a widespread health challenge. In response to this crisis, the article introduces Glucagon-Like Peptide-1 (GLP-1) medications as a potential bridge between our evolutionary past and modern challenges. GLP-1 agonists work by mimicking the natural GLP-1 hormone, which is released by the gut after eating. These medications slow gastric emptying, thereby prolonging feelings of fullness (satiety), and send signals to the brain that reduce appetite and hunger, ultimately leading to reduced food intake and weight loss. Clinical trials for drugs like semaglutide (found in Ozempic and Wegovy) have demonstrated significant weight loss. For instance, in a 64-week study, 76% of adults taking Wegovy lost 5% or more of their body weight, compared to 31% on placebo. A crucial point emphasized in the article, and corroborated by scientific literature, is that obesity is a chronic, relapsing condition requiring long-term treatment. Susan Jebb highlights that patients typically regain a significant amount of weight (about 10 kg out of 15 kg lost) within a year of discontinuing GLP-1 drugs, and this regain can be faster than after traditional dieting. This necessitates a shift in understanding obesity from a short-term problem to a condition requiring sustained management. The relevance of this story for an Indian audience is particularly high. India is grappling with a rapidly escalating obesity epidemic across all age groups. Data from the National Family Health Survey (NFHS) shows a 127% increase in overweight and obesity among under-five children between 2005-06 and 2019-21, with similar significant increases among adolescents and adults. Projections suggest that India's prevalence of overweight and obesity will continue to rise faster than the global average. Morbid obesity alone affects 5% of the country's population. This surge is attributed to factors like increasing consumption of processed foods, fast food, and sugary beverages, coupled with a decline in physical activity, especially in urban areas. GLP-1 medications are increasingly relevant in India. While Ozempic (semaglutide) is approved for type 2 diabetes management, it is widely prescribed off-label for weight loss under medical supervision. Dr. Reddy's Laboratories has received regulatory approval to produce a generic version of semaglutide in India, which is expected to improve accessibility and potentially affordability, as current proprietary drugs are expensive. The Indian government has also recognized the growing demand and potential for misuse, implementing stricter regulations to prevent unauthorized sales and ensure medically supervised use of GLP-1 drugs. The WHO, recognizing the transformative potential of GLP-1 therapies, released its first global guideline on December 1, 2025, conditionally recommending these drugs for adults with a BMI of 30 or higher. However, the WHO stresses that these drugs should always be part of a comprehensive, lifelong plan that includes healthy diets, regular physical activity, and professional counseling, reinforcing the idea that medication alone is not a magic bullet. Common side effects of GLP-1 agonists are primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which often decrease over time. Rarer but serious side effects can include gallbladder problems and pancreatitis, although long-term studies have largely dispelled concerns about pancreatic cancer. The long-term safety profile of GLP-1s is generally favorable, with some studies even suggesting protective effects on cardiovascular health and renal outcomes. The benefits of these drugs extend beyond weight loss, improving metabolic health and reducing risks of associated conditions like diabetes, heart disease, and some cancers. In conclusion, the article provides a well-grounded overview of the global obesity crisis, its evolutionary roots, and the emerging role of GLP-1 medications. It accurately portrays these drugs as powerful tools that offer significant benefits in weight management, particularly when integrated into a holistic, long-term care strategy, emphasizing the need for continued treatment and medical oversight. The context for India highlights a critical public health challenge that these medications could help address, alongside necessary lifestyle changes and robust regulatory frameworks.

Frequently Asked Questions

Read Full Story on Quick Digest